BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded ...

SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 randomized, ...

First patient dosed with ZI-MA4-1 in the ZIMA-101 Phase 1 trial at The Christie NHS Foundation TrustZI-MA4-1 is the world’s first MAGE-A4-targeting TCR-NK therapy in clinical developmentZIMA-101 ...

OSLO, Norway--(BUSINESS WIRE)--Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced the ...

All Active Patients in Both Cohorts Have Successfully Reached Highest Target Doses of 48 mg and 64 mg Topline Data Remains on Track for Fourth Quarter 2026 CAMBRIDGE ...

Data support AGAMREE®’s potential use as a treatment across a broad range of chronic inflammatory rare diseases ...

BAT8008, a TROP-2 antibody-drug conjugate (ADC), in patients with advanced solid tumor: Results from a phase 1 study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...

Favorable Safety Profile Supports Long-Term Chronic Dosing: PAS-004 has been well-tolerated, with all treatment-related adverse events ...

Phase 1/2a Clinical Trial to Evaluate Safety and Preliminary Efficacy of CRG-150 in Metastatic Triple-Negative Breast Cancer, HR+ HER2− Breast Cancer, and Prostate Cancer at Leading Academic Medical ...

Data support AGAMREE's potential use as a treatment across a broad range of chronic inflammatory rare diseases Pratteln, Switzerland, July 1, 2026 - Santhera Pharmaceuticals (SIX: SANN) today notes ...